Resultats de la cerca - Kai Michael Beeh

  • Mostrar 1 - 18 resultats de 18
Refinar resultats
  1. 1
    Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial

    Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial per Kai Michael Beeh, Dave Singh, Di Scala, Drollmann

    Publicat 2012
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects

    Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibro... per Kai Michael Beeh, Jutta Beier, Oliver Kornmann, Roland Buhl

    Publicat 2003
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Glutathione deficiency of the lower respiratory tract in patients with idiopathic pulmonary fibrosis

    Glutathione deficiency of the lower respiratory tract in patients with idiopathic pulmonary fibrosis per Kai Michael Beeh, Jutta Beier, I.C. Haas, Oliver Kornmann, Patrick Micke, Roland Buhl

    Publicat 2002
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study

    Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study per Kai-Michael Beeh, Stephanie Korn, Jutta Beier, Dalal Jadayel, Michelle Henley, Peter D’Andrea, Donald Banerji

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma

    Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma per Kai-Michael Beeh, Petra Moroni-Zentgraf, Othmar Ablinger, Zuzana Hollaenderova, Anna Unseld, Michael Engel, Stephanie Korn

    Publicat 2014
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and luticasone propionate via Accuhaler® (ENERGITO® study)

    The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and luticasone propionate via Accuhal... per Kai Michael Beeh, Eric Derom, José Echave-Sustaeta, Lars Grönke, Alan Hamilton, Dongmei Zhai, Leif Bjermer

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial

    Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial per Kai Michael Beeh, Thomas Glaab, Susanne Stowasser, Hendrik Schmidt, Leonardo M. Fabbri, Klaus F. Rabe, Claus Vogelmeier

    Publicat 2013
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease

    The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease per Kai-Michael Beeh, Jan Westerman, Anne‐Marie Kirsten, Jacques Hébert, Lars Grönke, Alan Hamilton, Kay Tetzlaff, Eric Derom

    Publicat 2015
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    The environmental impact of inhaled therapy: making informed treatment choices

    The environmental impact of inhaled therapy: making informed treatment choices per Ashley Woodcock, Kai Michael Beeh, Hironori Sagara, Simon Aumônier, Emmanuel Addo‐Yobo, Javaid Ahmed Khan, Jørgen Vestbo, Helen Tope

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  10. 10
    Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial

    Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial per Kai Michael Beeh, Henrik Watz, Luís Puente‐Maestu, Luis de Teresa, Diana Jarreta, Cynthia Caracta, Esther Garcia Gil, H Magnussen

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD

    Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD per Claus Vogelmeier, Bettina Hederer, Thomas Glaab, Hendrik Schmidt, Maureen Rutten‐van Mölken, Kai Michael Beeh, Klaus F. Rabe, Leonardo M. Fabbri

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD

    ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD per Henrik Watz, Thierry Troosters, Kai Michael Beeh, Judith García‐Aymerich, Pierluigi Paggiaro, Eduard Molins, Massimo Notari, Antonio Zapata, Diana Jarreta, Esther Garcia Gil

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study

    A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study per Kenneth R. Chapman, Kai Michael Beeh, Jutta Beier, Eric Bateman, Anthony D’Urzo, Robert Nutbrown, Michelle Henley, Hungta Chen, Tim Overend, Peter D’Andrea

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD

    Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD per Dave Singh, Kai Michael Beeh, Brendan Colgan, Oliver Kornmann, Brian Leaker, Henrik Watz, Germano Lucci, Silvia Geraci, Aida Emirova, Mirco Govoni, Marie Anna Nandeuil

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis

    Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis per Fabiano Di Marco, Giovanni Sotgiu, Pierachille Santus, Denis E. O’Donnell, Kai Michael Beeh, Simone Dore, Maria Adelaide Roggi, Lisa Giuliani, Francesco Blasi, Stefano Centanni

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  16. 16
    INTREPID: single-<i>versus</i>multiple-inhaler triple therapy for COPD in usual clinical practice

    INTREPID: single-<i>versus</i>multiple-inhaler triple therapy for COPD in usual clinical practice per David Halpin, Sally Worsley, Afisi Ismaila, Kai-Michael Beeh, Dawn Midwinter, Janwillem Kocks, Elaine Irving, José M. Marı́n, Neil Martin, Maggie Tabberer, Neil G. Snowise, Chris Compton

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?

    How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease? per Kai Michael Beeh, Pierre‐Régis Burgel, Frits M.E. Franssen, José Luís López-Campos, Stelios Loukides, John R. Hurst, Matjaž Fležar, Charlotte Suppli Ulrik, Fabiano Di Marco, Daiana Stolz, Arschang Valipour, Brian Casserly, Björn Ställberg, Κonstantinos Κostikas, Jadwiga A. Wedzicha

    Publicat 2017
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  18. 18
    Allergen-Induced Asthmatic Responses Modified by a GATA3-Specific DNAzyme

    Allergen-Induced Asthmatic Responses Modified by a GATA3-Specific DNAzyme per Norbert Krug, Jens M. Hohlfeld, Anne‐Marie Kirsten, Oliver Kornmann, Kai Michael Beeh, Dominik Kappeler, Stephanie Korn, Stanislav Ignatenko, Wolfgang Timmer, Cordelia Rogon, Jana Zeitvogel, Nan Zhang, Joachim Bille, Ursula Homburg, Agnieszka Turowska, Claus Bachert, Thomas Werfel, Roland Buhl, Jonas Renz, Holger Garn, Harald Renz

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: